Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

• Status: Completed
• Trial end date: 2014-07-01

Summary

1. To evaluate the pharmacokinetics (PK) and relative bioavailability of TG-2349, given as a new capsule formulation and as the original formulation of oral solution, after a single oral dose of 400 mg under fed condition in healthy volunteers.

2. To evaluate the safety and tolerability of TG-2349 in healthy volunteers.

3. To evaluate the ethnic differences in PK and safety between East Asian and Caucasian volunteers.

• Phase: Phase 1

Details

• Lead Sponsor: TaiGen Biotechnology Co., Ltd.